Lysodren and Shock haemorrhagic - a phase IV clinical study of FDA data


Shock haemorrhagic is found among people who take Lysodren, especially for people who are female, 60+ old, have been taking the drug for < 1 month.

The phase IV clinical study analyzes which people take Lysodren and have Shock haemorrhagic. It is created by eHealthMe based on reports of 747 people who have side effects when taking Lysodren from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Aug, 17, 2022

747 people reported to have side effects when taking Lysodren.
Among them, 13 people (1.74%) have Shock haemorrhagic.

What is Lysodren?

Lysodren has active ingredients of mitotane. eHealthMe is studying from 628 Lysodren users for its effectiveness, alternative drugs and more.

What is Shock haemorrhagic?

Shock haemorrhagic (a life-threatening condition with symptoms like low blood pressure, weakness, shallow breathing, cold, clammy skin due to excess bleeding) is found to be associated with 994 drugs and 743 conditions by eHealthMe.

Number of Lysodren and Shock haemorrhagic reports submitted per year:

Could Lysodren cause Shock haemorrhagic?

Time on Lysodren when people have Shock haemorrhagic *:

  • < 1 month: 69.23 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 23.08 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 7.69 %

Gender of people who have Shock haemorrhagic when taking Lysodren *:

  • female: 92.31 %
  • male: 7.69 %

Age of people who have Shock haemorrhagic when taking Lysodren *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 8.33 %
  • 60+: 91.67 %

Common drugs people take besides Lysodren *:

  1. Mucomyst: 9 people, 69.23%
  2. Aldactone: 9 people, 69.23%
  3. Omeprazole: 7 people, 53.85%
  4. Enalapril Maleate: 7 people, 53.85%
  5. Zolpidem Tartrate: 5 people, 38.46%
  6. Spironolactone: 2 people, 15.38%
  7. Acetylcysteine: 2 people, 15.38%
  8. Symbicort: 1 person, 7.69%
  9. Fludrocortisone Acetate: 1 person, 7.69%

Common side effects people have besides Shock haemorrhagic *:

  1. Adrenal Insufficiency (condition in which the adrenal glands do not produce adequate amounts of steroids): 13 people, 100.00%
  2. Anaemia (lack of blood): 10 people, 76.92%
  3. Hypovolaemic Shock (shock caused by severe blood or fluid loss): 10 people, 76.92%
  4. Hyperkalemia (damage to or disease of the kidney): 9 people, 69.23%
  5. Lymphopenia (an abnormally low level of lymphocytes in the blood): 8 people, 61.54%
  6. Thrombocytopenia (decrease of platelets in blood): 8 people, 61.54%
  7. General Physical Health Deterioration (weak health status): 8 people, 61.54%
  8. Acute Kidney Failure: 7 people, 53.85%
  9. Tumor Necrosis: 7 people, 53.85%
  10. Adrenal Neoplasm (abnormal growth of adrenal gland): 6 people, 46.15%

Common conditions people have *:

  1. Hyperadrenocorticism (overproduction of cortisol): 8 people, 61.54%
  2. Ill-Defined Disorder: 2 people, 15.38%
  3. Adrenocortical Carcinoma (adrenal cortex cancer): 2 people, 15.38%

* Approximation only. Some reports may have incomplete information.

Do you take Lysodren and have Shock haemorrhagic?

Check whether Shock haemorrhagic is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Related studies

How severe was Shock haemorrhagic and when was it recovered:

Expand to all the drugs that have ingredients of mitotane:

Alternative drugs to, pros and cons of Lysodren:

Shock haemorrhagic treatments and more:

COVID vaccines that are related to Shock haemorrhagic:

Common drugs associated with Shock haemorrhagic:

All the drugs that are associated with Shock haemorrhagic:

Common conditions associated with Shock haemorrhagic:

All the conditions that are associated with Shock haemorrhagic:

How the study uses the data?

The study uses data from the FDA. It is based on mitotane (the active ingredients of Lysodren) and Lysodren (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: